MedTrace Logo

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

NCT02985190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-04

No results posted yet for this study

Summary

This study is a phase II of effcicacy and tolerance of azacitidine in patients with myelodysplatic syndrome and steroid dependent or resistent systemic auto-immune and inflammatory disorders

Conditions

  • MDS
  • Systemic Autoimmune Diseases

Interventions

DRUG

Azacitidine

Azacitidine at 75mg/m²/j for 7 days.

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Groupe Francophone des Myelodysplasies

    lead OTHER

Principal Investigators

  • Arsene MEKINIAN, MD · Saint Antoine Hospital

  • Olivier FAIN, PHD · Saint Antoine Hospital

  • Pierre FENAUX, PHD · Saint-Louis Hospital, Paris, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-26
Primary Completion
2021-09-02
Completion
2022-08-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02985190 on ClinicalTrials.gov